Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Noriyoshi Kobayashi is active.

Publication


Featured researches published by Noriyoshi Kobayashi.


Nephron | 2002

Serum Cystatin C Is a More Sensitive Marker of Glomerular Function than Serum Creatinine

Ayumi Shimizu-Tokiwa; Mami Kobata; Hiroaki Io; Noriyoshi Kobayashi; Ichiyu Shou; Kazuhiko Funabiki; Mitsumine Fukui; Satoshi Horikoshi; Isao Shirato; Kensuke Saito; Yasuhiko Tomino

We determined the relationship between the levels of serum cystatin C or creatinine (s-Cr) and the grade of creatinine clearance (CCr) in patients with various glomerular diseases. Serum samples from 96 patients with glomerular diseases were obtained from our hospital. The levels of serum cystatin C were measured using the Dade Behring Cystatin C assay with the automated Dade Behring Nephelometer II (BNII). CCr levels were classified into six groups according to the Guidelines of the Japanese Society of Nephrology as follows: grade 1 (normal renal function); grade 2 (slight decrease of renal function); grade 3 (moderate decrease of renal function); grade 4 (severe decrease of renal function); grade 5 (renal failure), and grade 6 (uremia). The mean levels of serum cystatin C in grade 3 patients were significantly higher than those in grade 1. The mean levels of serum cystatin C in grades 4, 5 and 6 patients were also significantly higher than those in grade 1. However, the mean levels of serum Cr in grade 3 patients were not significantly higher than those in grade 1. The levels of s-Cr in grades 4, 5 or 6 patients were significantly higher than those in grade 1. In this study, an increase of serum cystatin C levels occurred earlier than that of s-Cr in various glomerular diseases. It appears that the levels of serum cystatin C may provide early prognostic marker of patients with various glomerular diseases rather than the levels of s-Cr.


Nephrology Dialysis Transplantation | 2010

Down-regulation of core 1 β1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1

Koshi Yamada; Noriyoshi Kobayashi; Tomomi Ikeda; Yusuke Suzuki; Toshinao Tsuge; Satoshi Horikoshi; Steven N. Emancipator; Yasuhiko Tomino

Background. Patients with IgA nephropathy (IgAN) have an increased amount of abnormally O-glycosylated IgA1 in circulation, in glomerular deposits and produced by tissue cells in vitro. Although increased production of Th2 cytokines by peripheral blood lymphocytes and a functional abnormality of core 1 β1,3-galactosyltransferase (C1β3Gal-T) have been proposed as mechanisms underlying pathogenesis of IgAN, they are still obscure and are not connected. Methods. To clarify the effect of T-cell cytokines, we analysed the mRNA levels of C1β3Gal-T and its molecular chaperone Cosmc, C1β3Gal-T activity and subsequent O-glycosylation of IgA1 in a human B-cell line stimulated with these cytokines. The surface IgA1-positive human B-cell line was cultured with recombinant human IFN-γ, IL-2, IL-4 or IL-5. The production and glycosylation of IgA1 were determined by sandwich ELISA and enzyme-linked lectin binding assay, respectively. The mRNA levels of C1β3Gal-T and Cosmc were quantitatively measured by real-time PCR. C1β3Gal-T activity was analysed using high-performance liquid chromatography. Results. IgA1 production by IL-4-stimulated cells was significantly higher than controls or after IFN-γ or IL-5. The terminal glycosylation of secreted IgA1 was altered in response to IL-4. IL-4 stimulation significantly decreased the mRNA levels of both C1β3Gal-T and Cosmc and of C1β3Gal-T activity. IL-4 stimulation was clearly blocked by recombinant human IL-4 soluble receptor. Conclusions. It appears that Th2 cytokine IL-4 may play a key role in controlling glycosylation of the IgA1 hinge region.


Nephron | 2002

Effects of Oral Adsorbent AST-120 (Kremezin®) on Renal Function and Glomerular Injury in Early-Stage Renal Failure of Subtotal Nephrectomized Rats

Noriyoshi Kobayashi; Atsuko Maeda; Satoshi Horikoshi; Isao Shirato; Yasuhiko Tomino; Michihito Ise

The aim of the present study was to determine if treatment with an oral adsorbent (AST-120, Kremezin®) might decrease the urinary albumin excretion and serum indoxyl sulfate (s-IS), and prevent glomerular sclerosis in early-stage renal failure, i.e. 0.9–1.2 mg/dl of serum creatinine (s-Cr) and 60–95 mg/dl of blood urea nitrogen (BUN), in subtotal (3/4) nephrectomized rats. Levels of s-Cr and s-IS in the AST-120-treated rats were significantly lower than those in the untreated control rats. The AST-120-treated rats showed an increase of creatinine clearance. Urinary protein and indoxyl sulfate excretion in the AST-120-treated rats were also significantly lower than those in the untreated control rats. The ratio of glomerular tuft area to the area of Bowman’s capsules (GT/BC) in the AST-120-treated rats was significantly lower than that in the untreated control rats. The degree of glomerular sclerosis and tubulointerstitial fibrosis in the AST-120-treated rats was significantly lower than that in the untreated control rats. Furthermore, there was a significant relationship among the degree of GT/BC, glomerular sclerosis, tubulointerstitial fibrosis and the levels of urinary protein excretion. It appears that AST-120 might decrease the accumulation of s-Cr and s-IS, and prevent glomerular sclerosis in early stage renal failure in the subtotal nephrectomized rats.


Modern Rheumatology | 2011

Three cases of PR3-ANCA positive subacute endocarditis caused by attenuated bacteria (Propionibacterium, Gemella, and Bartonella) complicated with kidney injury

Kenji Satake; Isao Ohsawa; Noriyoshi Kobayashi; Ken Osaki; Hitoe Toyoda; Satoshi Horikoshi; Yasuhiko Tomino

Subacute bacterial endocarditis (SBE) associated with antiproteinase-3 antineutrophil cytoplasmic antibodies (PR3-ANCA) has previously been reported in 10 cases of Streptococcus viridans and in 1 case of Escherichia faecalis infection. Most of these patients had hypocomplementemia and were positive for several autoantibodies. The infections in most of these patients showed good responses to antibiotic treatment. We report three patients with ANCA-positive SBE, which was induced by attenuated slow-growing intracellular pathogens; these patients had severe complications, such as acute kidney injury, cerebral embolism, and aortic valve destruction.


Journal of Clinical Laboratory Analysis | 2012

Risk of overestimation of kidney function using GFR-estimating equations in patients with low inulin clearance.

Junichiro Nakata; Isao Ohsawa; Kisara Onda; Mitsuo Tanimoto; Gaku Kusaba; Yukihiko Takeda; Noriyoshi Kobayashi; Katsuhiko Asanuma; Yuichi Tanaka; Michiko Sato; Yuko Inami; Hitoshi Suzuki; Hiyori Suzuki; Atsumi Masuda; Kanae Nonaka; Yu Sasaki; Atsuko Hisada; Chieko Hamada; Satoshi Horikoshi; Yasuhiko Tomino

Accurate estimation of the glomerular filtration rate (GFR) is very important in clinical practice. Although renal inulin clearance (Cin) is the gold standard for measuring GFR, the procedure for Cin measurement is complicated. Use of GFR‐estimating equations has been increasing recently due to their simplicity. The objectives of the present study are to analyze the correlation between Cin and other GFR‐estimating parameters and to investigate their clinical usefulness and limitation.


Journal of Nephrology | 2011

One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease.

Yasuhiko Tomino; Yoshio Shimizu; Chieko Hamada; Atsushi Kurusu; Isao Ohsawa; Yusuke Suzuki; Toshinao Tsuge; Hiroaki Io; Noriyoshi Kobayashi; Yukihiko Takeda; Katsuhiko Asanuma; Yuichi Tanaka; Hitoshi Suzuki; Junichiro Nakata; Katsuhiko Takara; Satoshi Horikoshi

BACKGROUND The long-term antiproteinuric effects of benidipine, a calcium channel blocker (CCB), have not been evaluated in detail in hypertensive patients with chronic kidney disease (CKD). METHODS Benidipine (4 mg/day) was administered to previously untreated hypertensive patients with CKD, or hypertensive patients with CKD not achieving target blood pressure (BP) despite taking an angiotensin II receptor blocker (ARB). The patients were followed up for 1 year. If target BP was not achieved by 2 weeks after the start of benidipine treatment, the dosage was increased to 8 mg/day. The urinary protein to creatinine (UP/cre) ratio was evaluated before and after benidipine treatment. RESULTS This study evaluated 65 hypertensive patients with CKD. BP (systolic/diastolic) decreased from 154 ± 19 / 91 ± 12 mm Hg before treatment to 134 ± 16 / 78 ± 10 mm Hg at 1 year after treatment (p<0.001). The UP/cre ratio decreased significantly from 2.21 ± 2.47 g/g creatinine (g/g cre) before treatment to 1.43 ± 2.21 g/g cre after treatment (p<0.001). In both the untreated and ARB-treated groups, the BP and UP/cre ratio decreased significantly at 1 year after treatment. The percentage change in the UP/cre ratio was significantly greater in patients aged 65 years or older than in those less than 65 years (79.1% vs. 48.7%, p=0.038). CONCLUSIONS Benidipine treatment reduced the UP/cre ratio in hypertensive patients with CKD, and the percentage decrease of the UP/cre ratio was greater in elderly patients, suggesting that benidipine may have more potent antiproteinuric effects in elderly hypertensive patients with CKD.


Contributions To Nephrology | 2007

Analysis of innate immune responses in a model of IgA nephropathy induced by Sendai virus.

Michifumi Yamashita; Subba R. Chintalacharuvu; Noriyoshi Kobayashi; John G. Nedrud; Michael E. Lamm; Yasuhiko Tomino; Steven N. Emancipator

In a model of IgA nephropathy (IgAN) induced by Sendai virus (SeV) without Th1/Th2 polarizing immunization, Th2-prone BALB/c mice develop more severe nephritis with acute renal insufficiency than Th1-prone C3H mice. To determine whether Th1 or Th2 predominance influences the severity of experimental IgAN in mice, we employed polarizing immunizations in a SeV-induced IgAN model in Th1-prone C57Bl/6 mice and Th2-prone BALB/c mice. C57Bl/6 mice, immunized with SeV +CFA or +IFA, showed: (1) clear cytokine polarity by splenocytes in recall assays. (2) Total serum IgA and especially SeV-specific IgA from the IFA group showed a selective defect in galactosylation, not seen in the CFA group, and (3) serum creatinine in the IFA group was higher than in the CFA group or nonimmune controls. However, BALB/c mice did not show clear cytokine polarity with CFA/IFA adjuvant. Moreover, spleen cells from naive BALB/c mice produce IFN-gamma (but not IL-2, -4, -5, or -13) upon stimulation with inactivated SeV in vitro. By flow cytometry, IFN-gamma producing cells are CD3(-), CD19(-), CD49b(+) natural killer cells. IFN-gamma production by naive splenocytes is blocked partially by anti-IL12 blocking Abs, and completely by anti-IL18R blocking Abs. In conclusion, C57Bl/6 mice with polarizing priming with SeV showed clear cytokine polarity and distinct kidney injuries. However, BALB/c mice did not show clear cytokine polarity in the same immunizing system, presumably due to the effects of innate responses to SeV upon antigen-specific lymphocytes. Natural IFN-gamma production may influence the risk of renal failure in IgAN.


American Journal of Physiology-renal Physiology | 2002

FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells.

Noriyoshi Kobayashi; Yusuke Suzuki; Toshinao Tsuge; Ko Okumura; Chisei Ra; Yasuhiko Tomino


Journal of Nephrology | 2002

Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.

Zheng Y; Shirato I; Maeda A; Noriyoshi Kobayashi; Jie Liao; Shou I; Mitsumine Fukui; Yasuhiko Tomino


Nephrology | 2006

Alteration of IgA1 glycosylation by down-regulation of core 1 β1,3-galactosyltransferase and its molecular chaperone Cosmc by Th2 cytokine

Koshi Yamada; Noriyoshi Kobayashi; Tomomi Ikeda; Toshinao Tsuge; Yusuke Suzuki; Satoshi Horikoshi; Yasuhiko Tomino

Collaboration


Dive into the Noriyoshi Kobayashi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge